Video

Dr. Miron on first-line treatment selection in bladder cancer

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Benjamin Miron, MD, shares his expertise on treatment selection in the first-line setting for patients with urothelial carcinoma.

      Miron, a second-year hematology/oncology fellow at Fox Chase Cancer Center, presented a real-world study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on overall survival outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.